Biotest (BIO) Stock Overview
Develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
BIO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Biotest Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €37.60 |
| 52 Week High | €45.60 |
| 52 Week Low | €35.00 |
| Beta | 0.0019 |
| 1 Month Change | -5.05% |
| 3 Month Change | -10.48% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -8.29% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| BIO | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -4.6% | 0.06% | 2.7% |
| 1Y | n/a | -28.8% | 14.5% |
Return vs Industry: Insufficient data to determine how BIO performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how BIO performed against the German Market.
Price Volatility
| BIO volatility | |
|---|---|
| BIO Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 12.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: BIO has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine BIO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 2,495 | Jorg Schuttrumpf | www.biotest.com |
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis.
Biotest Aktiengesellschaft Fundamentals Summary
| BIO fundamental statistics | |
|---|---|
| Market cap | €1.32b |
| Earnings (TTM) | -€24.50m |
| Revenue (TTM) | €635.20m |
Is BIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIO income statement (TTM) | |
|---|---|
| Revenue | €635.20m |
| Cost of Revenue | €487.90m |
| Gross Profit | €147.30m |
| Other Expenses | €171.80m |
| Earnings | -€24.50m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Nov 10, 2025
| Earnings per share (EPS) | -0.62 |
| Gross Margin | 23.19% |
| Net Profit Margin | -3.86% |
| Debt/Equity Ratio | 131.2% |
How did BIO perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/05 00:53 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biotest Aktiengesellschaft is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Volker Braun | Commerzbank AG |
| Martin Possienke | GSN North America |
| Torben Teichler | Hauck Aufhäuser Investment Banking |